Dyadic International (DYAI) Change in Account Payables (2018 - 2026)
Dyadic International (DYAI) posted Change in Account Payables of $222697.0 for Q1 2026, up 160.66% sequentially from -$367095.0 in Q4 2025, and up 622.95% YoY from $30804.1 in Q1 2025.
Dyadic International (DYAI) Change in Account Payables (2018 - 2026) Analysis & Trends
Dyadic International has reported Change in Account Payables for 9 years, with the latest figure at $222697.0 in Q1 2026.
- Quarterly Change in Account Payables rose 622.95% year-over-year to $222697.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $579733.0 (up 354.3% YoY) and the FY2025 annual result came in at $314451.0, up 274.52% from the prior year.
- Change in Account Payables grew to $222697.0 in Q1 2026 per DYAI's latest filing, from -$367095.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $468836.0 in Q4 2022 and troughed at -$679918.0 in Q1 2022.
- A 5-year average of -$31901.8 and a median of $5201.0 in 2024 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2025 and 2026: Change in Account Payables tumbled 918.78% in 2025, then surged 622.95% in 2026.
- Over 5 years, Change in Account Payables stood at $468836.0 in 2022, then plunged by 91.4% to $40303.0 in 2023, then sank by 275.56% to -$70756.0 in 2024, then slumped by 418.82% to -$367095.0 in 2025, then jumped by 160.66% to $222697.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $222697.0, -$367095.0, and $457466.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | 222,697.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 222,697.00 |
| Mar 31, 2026 | 222,697.00 |
| Dec 31, 2025 | -367,095.00 |
| Dec 31, 2025 | -367,095.00 |
| Sep 30, 2025 | 457,466.00 |
| Sep 30, 2025 | 457,466.00 |
| Jun 30, 2025 | 266,665.00 |
| Jun 30, 2025 | 266,665.00 |
| Mar 31, 2025 | -42,585.00 |
| Mar 31, 2025 | -42,585.00 |
| Dec 31, 2024 | -70,756.00 |
| Dec 31, 2024 | -70,756.00 |
| Sep 30, 2024 | 114,881.00 |
| Sep 30, 2024 | 114,881.00 |
| Jun 30, 2024 | -229,508.00 |
| Jun 30, 2024 | -229,508.00 |
| Mar 31, 2024 | 5,201.00 |
| Mar 31, 2024 | 5,201.00 |
| Dec 31, 2023 | 40,303.00 |
| Dec 31, 2023 | 40,303.00 |